Cargando…
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33...
Autores principales: | Azoitei, Ninel, Hoffmann, Christopher M., Ellegast, Jana M., Ball, Claudia R., Obermayer, Kerstin, Gößele, Ulrike, Koch, Britta, Faber, Katrin, Genze, Felicitas, Schrader, Mark, Kestler, Hans A., Döhner, Hartmut, Chiosis, Gabriela, Glimm, Hanno, Fröhling, Stefan, Scholl, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328372/ https://www.ncbi.nlm.nih.gov/pubmed/22451720 http://dx.doi.org/10.1084/jem.20111910 |
Ejemplares similares
-
STK33 participates to HSP90-supported angiogenic program in hypoxic tumors by regulating HIF-1α/VEGF signaling pathway
por: Liu, Yang, et al.
Publicado: (2017) -
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells
por: Rouhi, Arefeh, et al.
Publicado: (2016) -
Physical plasma-triggered ROS induces tumor cell death upon cleavage of HSP90 chaperone
por: Bekeschus, Sander, et al.
Publicado: (2019) -
PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation
por: Azoitei, Ninel, et al.
Publicado: (2016) -
Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines
por: Stolze, Britta, et al.
Publicado: (2015)